Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04480645 · ClinicalTrials.gov registry record · Early Phase 1
CivaDerm(TM) Surface Therapy Pilot Study
A Early Phase 1 study of Basal Cell Carcinoma and Squamous Cell Carcinoma of the Skin, sponsored by CivaTech Oncology.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04480645: Recruiting Early Phase 1 study of Basal Cell Carcinoma and Squamous Cell Carcinoma of the Skin, sponsored by CivaTech Oncology.
NCT04480645 is a Early Phase 1 study of Basal Cell Carcinoma and Squamous Cell Carcinoma of the Skin that is actively recruiting participants, run by CivaTech Oncology. The registered enrollment target is 10 participants, below the 104-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04480645, a Early Phase 1 study of Basal Cell Carcinoma and Squamous Cell Carcinoma of the Skin, is actively recruiting participants, sponsored by CivaTech Oncology.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study to determine the usefulness of new brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit basal cell and squamous cell carcinoma patients by providing conformal radiation therapy to the surface of the skin.
Primary Outcome
grade 3+ events
Conditions Studied
Interventions
- DEVICE CivaDerm
Study Locations (1)
North Carolina
- CivaDerm Oncology PLLC - Morrisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2026-04-30 |
| Phase | Early Phase 1 |
What NCT04480645 shows while recruiting
NCT04480645 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 104-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Basal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which CivaDerm is the first listed.
NCT04480645 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT04480645 about?
NCT04480645 is a clinical study titled "CivaDerm(TM) Surface Therapy Pilot Study". This is a pilot study to determine the usefulness of new brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit basal cell and squamous cell carcinoma patients by providing conformal radiation therapy to the surface of the...
What is the current status of trial NCT04480645?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2024-05-01. Estimated completion is 2026-04-30.
What conditions does trial NCT04480645 study?
This clinical trial studies the following conditions: Basal Cell Carcinoma, Squamous Cell Carcinoma of the Skin.
What interventions are being tested in trial NCT04480645?
The interventions under investigation include: CivaDerm (DEVICE).
Who is sponsoring clinical trial NCT04480645?
This trial is sponsored by CivaTech Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04480645 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Basal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04480645's enrollment target sits among peer trials
10 25th of 24 the lowest of 24 other Basal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Basal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
RECRUITING · Phase 2
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
RECRUITING · Phase 2
-
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
RECRUITING · Phase 1
-
Investigation of Standard Excision Surgical Margins Using Two Photon Fluorescence Microscopy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI